Correction: Somatostatin receptor-targeted polymeric nanoplatform for efficient CRISPR/Cas9 gene editing to enhance synergistic hepatocellular carcinoma therapy

Correction: Journal of Nanobiotechnology (2025) 23:127

https://doi.org/10.1186/s12951-025-03214-3

In this article, Figs. 4a and 7b contained errors. These arose due to the complexity of dataset and an overly simplified file-naming convention during figure preparation, which unfortunately led to the misplacement of the original images. For completeness and transparency, the old incorrect versions and correct versions of Figs. 4 and 7 are displayed below.

Fig. 4.

Efficient gene editing achieved in vitro. (a) Representative fluorescence images of GFP-293T cells. (b) PD-L1 in HepG2 cells after treatment with different formulations. The cytotoxicity of different formulations treated HepG2 cells (c) and 293T cells (d). (e) Representative images of the wound healing assays in HepG2 cells from 0 to 72 h. (f) After 24 h of incubation with various formulations, the apoptosis status and overall apoptosis rate were assessed in HepG2 cells stained with FITC-Annexin V and propidium iodide (PI). All data are represented as means ± SD, n = 3

Fig. 7.

Safety evaluation. (a) Comparison of Alkaline phosphatase (ALP), alanine aminotransferase (ALT), aspartate aminotransferase (AST), and γ-glutamyltransferase (γ-GT) between control and drug treated mice by blood biochemical examination. (b) To examine the in vivo toxicity of different treatments, heart, liver, spleen, lung, and kidney of mice were deteced using H&E staining. Scale bar, 100 μm. All data are represented as means ± SD, n = 3

Incorrect Fig. 4.

Correct Fig. 4.

Incorrect Fig. 7.

Correct Fig. 7.

The original article has been corrected.